Romainville, France - May the 4th, 2007 - Cellectis SA, the rational genome engineering company developing a new range of custom DNA rewriting products for the research, healthcare and industrial sectors, today announced that it has granted GlaxoSmithKline a worldwide, non-exclusive sub-license to a patent family relating to a process for the specific replacement or insertion of a gene in a receiver genome by homologous recombination.
